|
Dr. Hanna is former Executive Vice President of Research at Biogen Idec. He assumed this responsibility after the merger of IDEC Pharmaceutical and Biogen in 2002. From 1990 to 2002, Dr. Hanna served as VP of Research then was promoted to Sr.VP of Research and Pre-Clinical Development and then Chief Scientific Officer at IDEC Pharmaceuticals. During his tenure at IDEC, Dr. Hanna led a research team through the discovery and pre-clinical development of Rituximab and Zevalin, two antibodies now approved for therapy of non-Hodgkin’s B cell lymphoma. From 1981 to 1990, Dr. Hanna served as a Director of the Department of Immunology at SmithKline Beecham focusing on autoimmune and chronic inflammatory diseases. From 1978 to 1981, he was a research scientist at the NCI-Frederick Cancer Research Center, where he studied the role of natural host defenses against cancer metastasis. From 1973 to 1978, Dr. Hanna was a lecturer in the Department of Immunology at Hebrew University Medical Center in Israel, where he received his Ph.D. in Immunology. | 